Cogent Biosciences IncNASDAQ:COGT
- LAST PRICE10.0800
- TODAY'S CHANGE (%)-0.8300 (-7.6077%)
- Bid / Lots10.0700/ 1
- Ask / Lots10.1900/ 4
- Open / Previous Close10.9500 / 10.9100
- Day Range
- 52 Week Range
- Volume457,657
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | COGT |
|---|---|---|
| 09:32 ET | 4232 | 10.7 |
| 09:34 ET | 500 | 10.748 |
| 09:36 ET | 900 | 10.6513 |
| 09:38 ET | 200 | 10.67 |
| 09:41 ET | 800 | 10.65 |
| 09:48 ET | 300 | 10.67 |
| 09:50 ET | 171 | 10.69 |
| 09:52 ET | 165 | 10.72 |
| 09:59 ET | 343 | 10.66 |
| 10:03 ET | 100 | 10.68 |
| 10:06 ET | 130 | 10.69 |
| 10:08 ET | 200 | 10.695 |
| 10:12 ET | 300 | 10.675 |
| 10:14 ET | 1186 | 10.68 |
| 10:15 ET | 200 | 10.65 |
| 10:17 ET | 800 | 10.64 |
| 10:19 ET | 200 | 10.66 |
| 10:24 ET | 400 | 10.66 |
| 10:28 ET | 1338 | 10.655 |
| 10:30 ET | 1000 | 10.645 |
| 10:32 ET | 100 | 10.645 |
| 10:33 ET | 1197 | 10.66 |
| 10:35 ET | 2150 | 10.695 |
| 10:37 ET | 400 | 10.705 |
| 10:42 ET | 936 | 10.68 |
| 10:44 ET | 600 | 10.65 |
| 10:46 ET | 100 | 10.625 |
| 10:48 ET | 100 | 10.62 |
| 10:50 ET | 1265 | 10.58 |
| 10:53 ET | 100 | 10.58 |
| 10:55 ET | 100 | 10.58 |
| 10:57 ET | 700 | 10.6 |
| 11:00 ET | 300 | 10.6 |
| 11:02 ET | 600 | 10.59 |
| 11:04 ET | 100 | 10.59 |
| 11:06 ET | 400 | 10.57 |
| 11:09 ET | 100 | 10.55 |
| 11:11 ET | 600 | 10.56 |
| 11:15 ET | 800 | 10.535 |
| 11:18 ET | 300 | 10.53 |
| 11:20 ET | 100 | 10.53 |
| 11:22 ET | 1229 | 10.53 |
| 11:24 ET | 1958 | 10.53 |
| 11:26 ET | 314 | 10.53 |
| 11:27 ET | 2522 | 10.51 |
| 11:29 ET | 1200 | 10.54 |
| 11:36 ET | 400 | 10.54 |
| 11:42 ET | 500 | 10.52 |
| 11:44 ET | 700 | 10.4856 |
| 11:45 ET | 100 | 10.5045 |
| 11:47 ET | 300 | 10.49 |
| 11:49 ET | 1505 | 10.468 |
| 11:54 ET | 300 | 10.47 |
| 11:56 ET | 600 | 10.45 |
| 11:58 ET | 401 | 10.45 |
| 12:00 ET | 700 | 10.42 |
| 12:02 ET | 391 | 10.42 |
| 12:03 ET | 300 | 10.44 |
| 12:05 ET | 100 | 10.46 |
| 12:07 ET | 392 | 10.4475 |
| 12:09 ET | 600 | 10.47 |
| 12:12 ET | 600 | 10.46 |
| 12:14 ET | 100 | 10.465 |
| 12:18 ET | 100 | 10.48 |
| 12:20 ET | 1069 | 10.49 |
| 12:21 ET | 745 | 10.51 |
| 12:23 ET | 1611 | 10.5145 |
| 12:25 ET | 200 | 10.53 |
| 12:30 ET | 1595 | 10.54 |
| 12:32 ET | 1827 | 10.51 |
| 12:34 ET | 1000 | 10.46 |
| 12:39 ET | 200 | 10.47 |
| 12:41 ET | 300 | 10.47 |
| 12:43 ET | 200 | 10.48 |
| 12:45 ET | 239 | 10.485 |
| 12:48 ET | 1420 | 10.545 |
| 12:50 ET | 200 | 10.555 |
| 12:52 ET | 2135 | 10.65 |
| 12:54 ET | 700 | 10.63 |
| 12:56 ET | 3074 | 10.65 |
| 12:59 ET | 700 | 10.65 |
| 01:01 ET | 200 | 10.64 |
| 01:06 ET | 1241 | 10.61 |
| 01:08 ET | 1796 | 10.61 |
| 01:10 ET | 1048 | 10.62 |
| 01:14 ET | 700 | 10.63 |
| 01:15 ET | 816 | 10.61 |
| 01:17 ET | 2879 | 10.63 |
| 01:21 ET | 34525 | 10.65 |
| 01:24 ET | 700 | 10.66 |
| 01:26 ET | 1015 | 10.66 |
| 01:28 ET | 900 | 10.7 |
| 01:30 ET | 1101 | 10.72 |
| 01:32 ET | 1400 | 10.68 |
| 01:33 ET | 1309 | 10.7 |
| 01:35 ET | 1200 | 10.69 |
| 01:37 ET | 600 | 10.7 |
| 01:39 ET | 460 | 10.7 |
| 01:42 ET | 900 | 10.65 |
| 01:44 ET | 800 | 10.6 |
| 01:46 ET | 200 | 10.58 |
| 01:48 ET | 100 | 10.605 |
| 01:50 ET | 1000 | 10.6 |
| 01:51 ET | 200 | 10.6 |
| 01:53 ET | 100 | 10.595 |
| 01:55 ET | 800 | 10.58 |
| 01:57 ET | 1230 | 10.615 |
| 02:00 ET | 542 | 10.61 |
| 02:02 ET | 1400 | 10.61 |
| 02:04 ET | 500 | 10.565 |
| 02:06 ET | 500 | 10.64 |
| 02:09 ET | 800 | 10.62 |
| 02:11 ET | 401 | 10.59 |
| 02:13 ET | 3527 | 10.6 |
| 02:15 ET | 4862 | 10.57 |
| 02:18 ET | 300 | 10.57 |
| 02:20 ET | 1419 | 10.59 |
| 02:22 ET | 600 | 10.56 |
| 02:24 ET | 1000 | 10.54 |
| 02:26 ET | 500 | 10.525 |
| 02:27 ET | 400 | 10.545 |
| 02:29 ET | 900 | 10.515 |
| 02:31 ET | 5247 | 10.49 |
| 02:33 ET | 600 | 10.49 |
| 02:36 ET | 2300 | 10.43 |
| 02:38 ET | 1400 | 10.42 |
| 02:40 ET | 300 | 10.43 |
| 02:42 ET | 1500 | 10.45 |
| 02:44 ET | 800 | 10.47 |
| 02:45 ET | 732 | 10.49 |
| 02:47 ET | 900 | 10.54 |
| 02:49 ET | 1200 | 10.555 |
| 02:51 ET | 1411 | 10.555 |
| 02:54 ET | 1000 | 10.48 |
| 02:56 ET | 3306 | 10.4876 |
| 02:58 ET | 600 | 10.48 |
| 03:00 ET | 1600 | 10.43 |
| 03:02 ET | 900 | 10.4 |
| 03:03 ET | 200 | 10.39 |
| 03:05 ET | 1200 | 10.39 |
| 03:07 ET | 1426 | 10.4 |
| 03:09 ET | 1100 | 10.39 |
| 03:12 ET | 400 | 10.39 |
| 03:14 ET | 1155 | 10.38 |
| 03:16 ET | 800 | 10.45 |
| 03:18 ET | 500 | 10.46 |
| 03:20 ET | 1100 | 10.44 |
| 03:21 ET | 1587 | 10.48 |
| 03:23 ET | 700 | 10.47 |
| 03:25 ET | 414 | 10.45 |
| 03:27 ET | 1208 | 10.415 |
| 03:30 ET | 700 | 10.43 |
| 03:32 ET | 2204 | 10.39 |
| 03:34 ET | 911 | 10.37 |
| 03:36 ET | 2387 | 10.3406 |
| 03:38 ET | 1400 | 10.32 |
| 03:39 ET | 2086 | 10.27 |
| 03:41 ET | 2580 | 10.26 |
| 03:43 ET | 4050 | 10.28 |
| 03:45 ET | 1400 | 10.23 |
| 03:48 ET | 3245 | 10.22 |
| 03:50 ET | 2952 | 10.23 |
| 03:52 ET | 3249 | 10.21 |
| 03:54 ET | 4967 | 10.18 |
| 03:56 ET | 7473 | 10.2 |
| 03:57 ET | 9913 | 10.15 |
| 03:59 ET | 66270 | 10.08 |
Mar 15, 2023
Needham Adjusts Price Target on Cogent Biosciences to $23 From $24, Keeps Buy Rating, from 7:44AM ET on Wednesday Mar 15, 2023 by MT Newswires
7:44AM ET on Wednesday Mar 15, 2023 by MT Newswires
Mar 14, 2023
Wedbush Adjusts Price Target on Cogent Biosciences to $20 From $19, Maintains Outperform Rating, from 10:58AM ET on Tuesday Mar 14, 2023 by MT Newswires
10:58AM ET on Tuesday Mar 14, 2023 by MT NewswiresBRIEF-Cogent Biosciences Reports Q4 Net Loss Per Share Of $0.56, from 9:16AM ET on Tuesday Mar 14, 2023 by Thomson Reuters
9:16AM ET on Tuesday Mar 14, 2023 by Thomson ReutersCogent Biosciences' Q4 Loss Narrows; Company Expects Cash Position to Fund Operations Into 2025, from 8:56AM ET on Tuesday Mar 14, 2023 by MT Newswires
8:56AM ET on Tuesday Mar 14, 2023 by MT NewswiresCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, from 8:00AM ET on Tuesday Mar 14, 2023 by GlobeNewswire
8:00AM ET on Tuesday Mar 14, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cogent Biosciences Inc | 763.1M | -4.1x | --- |
POINT Biopharma Global Inc | 769.1M | -7.9x | --- |
Allogene Therapeutics Inc | 774.5M | -2.2x | --- |
Viking Therapeutics Inc | 735.6M | -10.7x | --- |
Seres Therapeutics Inc | 767.8M | -2.5x | --- |
IGM Biosciences Inc | 731.0M | -2.8x | --- |
Company Information
Cogent Biosciences, Inc. is a biotechnology company that is focused on developing precision therapies for genetically defined diseases. The Company’s most advanced clinical program, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. The Company has initiated APEX, a Phase II clinical study of bezuclastinib in patients with AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib. It also initiated Peak, a randomized, open-label, global Phase III clinical trial.
Contact Information
- Headquarters
- 275 Wyman Street, 3Rd FloorWALTHAM, MA, United States 02451
- Phone
- 617-945-5576
- Fax
- ---
Executives
- Independent Chairman of the Board
- Peter Harwin
- President, Chief Executive Officer, Principal Executive Officer, Director
- Andrew Robbins
- Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
- John Green
- Chief Scientific Officer
- John Robinson
- Chief Medical Officer
- Jessica Sachs
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $763.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 69.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.76 |
EPS | $-2.45 |
Book Value | $3.66 |
P/E Ratio | -4.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
